Evidence map›Paper›PMID 39705580›Full record

ArticleThe journal of extra-corporeal technology2024

Interaction of milrinone with extracorporeal life support.

Aviva J Whelan, Sabiha Mim, J Porter Hunt, Autumn M McKnite, Danielle J Green, Carina E Imburgia, Jeremiah D Momper, Gideon Stitt, Kevin M Watt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of extra-corporeal technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aviva J WhelanDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.ORCID 0000-0001-8968-3183
Sabiha MimPharmacometric Research Group, Department of Pharmacy, Uppsala University, Husargatan, Uppsala 752 37, Sweden.ORCID 0009-0005-9359-8527
J Porter HuntDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.ORCID 0000-0003-3503-8124
Autumn M McKniteDepartment of Pharmacology and Toxicology, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.ORCID 0000-0001-7985-2991
Danielle J GreenDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.
Carina E ImburgiaDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.
Jeremiah D MomperSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9255 Pharmacy Lane, MC 0657, La Jolla, CA 92093, USA.
Gideon StittDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.ORCID 0000-0001-5269-214X
Kevin M WattDivision of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.

Funding

Multidisciplinary Pulmonary and Critical Care Training ProgramT32HL105321 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Ramsey Hachem, Robert Paine · 2010 to 2026
$4.5M
Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life SupportR01HD097775 · NICHD · UNIVERSITY OF UTAH · PI WATT, KEVIN M · 2019 to 2023
$2.7M
NHLBI NIH HHS T32 HL105321NICHD NIH HHS R01 HD097775
6 · The paper itself

Abstract

backgroundMilrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.

methodsEx vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.

resultsMilrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.

conclusionMilrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.

Indexed as

Extracorporeal Membrane OxygenationMilrinoneContinuous Renal Replacement TherapyHumansMilrinoneContinuous renal replacement therapy (CRRT)Extracorporeal life support (ECLS)Extracorporeal membrane oxygenation (ECMO)Milrinone

Identifiers

PMID39705580
PMCPMC11661780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.